首页 > 最新文献

Cancer Investigation最新文献

英文 中文
TTYH3 Promotes Cervical Cancer Progression by Activating the Wnt/β-Catenin Signaling Pathway. TTYH3通过激活Wnt/β-Catenin信号通路促进宫颈癌进展
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.1080/07357907.2024.2395014
Xiuyan Huang, Qing Li, Xiaoxia Zheng, Chen Jiang

The role of tweety homolog 3 (TTYH3) has been studied in several cancers, including hepatocellular carcinoma, cholangiocarcinoma, and gastric cancer. The results showed that TTYH3 is highly expression in cervical cancer tissues and cells and high TTYH3 expression correlates with poor prognosis in patients with cervical cancer. TTYH3 markedly reduced the apoptosis rate and promoted proliferation, migration, and invasion. Silencing of TTYH3 has been shown to have an inhibitory effect on cervical cancer progression. Moreover, TTYH3 enhanced EMT and activated Wnt/β-catenin signaling. Furthermore, TTYH3 knockdown inhibited the tumor growth in vivo. In conclusion, TTYH3 promoted cervical cancer progression by activating the Wnt/β-catenin signaling.

有人研究了 Tweety homolog 3(TTYH3)在肝癌、胆管癌和胃癌等多种癌症中的作用。研究结果表明,TTYH3 在宫颈癌组织和细胞中高表达,TTYH3 的高表达与宫颈癌患者的不良预后相关。TTYH3 能显著降低细胞凋亡率,促进细胞增殖、迁移和侵袭。研究表明,沉默 TTYH3 对宫颈癌的进展有抑制作用。此外,TTYH3 还能增强 EMT 并激活 Wnt/β-catenin 信号转导。此外,敲除 TTYH3 可抑制体内肿瘤的生长。总之,TTYH3通过激活Wnt/β-catenin信号促进了宫颈癌的进展。
{"title":"TTYH3 Promotes Cervical Cancer Progression by Activating the Wnt/<b><i>β</i></b>-Catenin Signaling Pathway.","authors":"Xiuyan Huang, Qing Li, Xiaoxia Zheng, Chen Jiang","doi":"10.1080/07357907.2024.2395014","DOIUrl":"10.1080/07357907.2024.2395014","url":null,"abstract":"<p><p>The role of tweety homolog 3 (TTYH3) has been studied in several cancers, including hepatocellular carcinoma, cholangiocarcinoma, and gastric cancer. The results showed that TTYH3 is highly expression in cervical cancer tissues and cells and high TTYH3 expression correlates with poor prognosis in patients with cervical cancer. TTYH3 markedly reduced the apoptosis rate and promoted proliferation, migration, and invasion. Silencing of TTYH3 has been shown to have an inhibitory effect on cervical cancer progression. Moreover, TTYH3 enhanced EMT and activated Wnt/β-catenin signaling. Furthermore, TTYH3 knockdown inhibited the tumor growth in vivo. In conclusion, TTYH3 promoted cervical cancer progression by activating the Wnt/β-catenin signaling.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"726-739"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Cancer Diagnosis: Enhanced Deep Maxout Model with Improved Feature Set. 肝癌诊断:改进特征集的增强型深度 Maxout 模型
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.1080/07357907.2024.2391359
Vinnakota Sai Durga Tejaswi, Venubabu Rachapudi

This work proposed a liver cancer classification scheme that includes Preprocessing, Feature extraction, and classification stages. The source images are pre-processed using Gaussian filtering. For segmentation, this work proposes a LUV transformation-based adaptive thresholding-based segmentation process. After the segmentation, certain features are extracted that include multi-texon based features, Improved Local Ternary Pattern (LTP-based features), and GLCM features during this phase. In the Classification phase, an improved Deep Maxout model is proposed for liver cancer detection. The adopted scheme is evaluated over other schemes based on various metrics. While the learning rate is 60%, an improved deep maxout model achieved a higher F-measure value (0.94) for classifying liver cancer; however, the previous method like Support Vector Machine (SVM), Random Forest (RF), Recurrent Neural Network (RNN), Long Short Term Memory (LSTM), K-Nearest Neighbor (KNN), Deep maxout, Convolutional Neural Network (CNN), and DL model holds less F-measure value. An improved deep maxout model achieved minimal False Positive Rate (FPR), and False Negative Rate (FNR) values with the best outcomes compared to other existing models for liver cancer classification.

这项工作提出了一种肝癌分类方案,包括预处理、特征提取和分类三个阶段。使用高斯滤波对源图像进行预处理。在分割方面,这项研究提出了基于 LUV 变换的自适应阈值分割流程。分割完成后,在此阶段将提取某些特征,包括基于多节点的特征、改进的局部三元模式(基于 LTP 的特征)和 GLCM 特征。在分类阶段,提出了一种用于肝癌检测的改进型深度 Maxout 模型。根据各种指标对所采用的方案与其他方案进行了评估。在学习率为 60% 的情况下,改进的 Deep maxout 模型在肝癌分类方面取得了较高的 F-measure 值(0.94);然而,之前的方法,如支持向量机(SVM)、随机森林(RF)、循环神经网络(RNN)、长短期记忆(LSTM)、K-近邻(KNN)、Deep maxout、卷积神经网络(CNN)和 DL 模型的 F-measure 值较低。与其他现有的肝癌分类模型相比,改进后的 Deep maxout 模型的假阳性率(FPR)和假阴性率(FNR)值最小,效果最好。
{"title":"Liver Cancer Diagnosis: Enhanced Deep Maxout Model with Improved Feature Set.","authors":"Vinnakota Sai Durga Tejaswi, Venubabu Rachapudi","doi":"10.1080/07357907.2024.2391359","DOIUrl":"10.1080/07357907.2024.2391359","url":null,"abstract":"<p><p>This work proposed a liver cancer classification scheme that includes Preprocessing, Feature extraction, and classification stages. The source images are pre-processed using Gaussian filtering. For segmentation, this work proposes a LUV transformation-based adaptive thresholding-based segmentation process. After the segmentation, certain features are extracted that include multi-texon based features, Improved Local Ternary Pattern (LTP-based features), and GLCM features during this phase. In the Classification phase, an improved Deep Maxout model is proposed for liver cancer detection. The adopted scheme is evaluated over other schemes based on various metrics. While the learning rate is 60%, an improved deep maxout model achieved a higher <i>F</i>-measure value (0.94) for classifying liver cancer; however, the previous method like Support Vector Machine (SVM), Random Forest (RF), Recurrent Neural Network (RNN), Long Short Term Memory (LSTM), K-Nearest Neighbor (KNN), Deep maxout, Convolutional Neural Network (CNN), and DL model holds less <i>F</i>-measure value. An improved deep maxout model achieved minimal False Positive Rate (FPR), and False Negative Rate (FNR) values with the best outcomes compared to other existing models for liver cancer classification.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"710-725"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive Dysfunction in Non-CNS Metastatic Cancer: Comparing Brain Metastasis, Non-CNS Metastasis, and Healthy Controls. 非中枢神经系统转移性癌症的认知功能障碍:比较脑转移癌、非中枢神经系统转移癌和健康对照组
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1080/07357907.2024.2371368
Christopher Collette, Gabrielle Willhelm, Victor A Del Bene, Stephen L Aita, Dario Marotta, Terina Myers, Joseph Anderson, Meredith Gammon, Adam Gerstenecker, L Burt Nabors, John Fiveash, Kristen L Triebel

Limited research has compared cognition of people with non-central nervous system metastatic cancer (NCM) vs. metastatic brain cancer (BM). This prospective cross-sectional study was comprised 37 healthy controls (HC), 40 NCM, and 61 BM completing 10 neuropsychological tests. The NCM performed below HCs on processing speed and executive functioning tasks, while the BM group demonstrated lower performance across tests. Tasks of processing speed, verbal fluency, and verbal memory differentiated the clinical groups (BM < NCM). Nearly 20% of the NCM group was impaired on at least three neuropsychological tests whereas approximately 40% of the BM group demonstrated the same level of impairment.

对非中枢神经系统转移性癌症(NCM)患者与转移性脑癌(BM)患者的认知能力进行比较的研究十分有限。这项前瞻性横断面研究由 37 名健康对照组(HC)、40 名 NCM 和 61 名 BM 组成,他们完成了 10 项神经心理学测试。在处理速度和执行功能任务上,NCM 的表现低于健康对照组,而 BM 组在所有测试中的表现均低于健康对照组。在处理速度、言语流畅性和言语记忆等任务上,临床组(BM 至少完成了三项神经心理学测试,而 BM 组中约 40% 的人表现出了相同程度的障碍)的表现有所区别。
{"title":"Cognitive Dysfunction in Non-CNS Metastatic Cancer: Comparing Brain Metastasis, Non-CNS Metastasis, and Healthy Controls.","authors":"Christopher Collette, Gabrielle Willhelm, Victor A Del Bene, Stephen L Aita, Dario Marotta, Terina Myers, Joseph Anderson, Meredith Gammon, Adam Gerstenecker, L Burt Nabors, John Fiveash, Kristen L Triebel","doi":"10.1080/07357907.2024.2371368","DOIUrl":"10.1080/07357907.2024.2371368","url":null,"abstract":"<p><p>Limited research has compared cognition of people with non-central nervous system metastatic cancer (NCM) <i>vs.</i> metastatic brain cancer (BM). This prospective cross-sectional study was comprised 37 healthy controls (HC), 40 NCM, and 61 BM completing 10 neuropsychological tests. The NCM performed below HCs on processing speed and executive functioning tasks, while the BM group demonstrated lower performance across tests. Tasks of processing speed, verbal fluency, and verbal memory differentiated the clinical groups (BM < NCM). Nearly 20% of the NCM group was impaired on <i>at least</i> three neuropsychological tests whereas approximately 40% of the BM group demonstrated the same level of impairment.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"671-681"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of Invasive Cribriform Carcinoma. 浸润性楔形细胞癌的特征
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.1080/07357907.2024.2383930
Ryusei Yoshino, Masaki Nakatsubo, Nanami Ujiie, Akane Ito, Nana Yoshida, Masahiro Kitada

Invasive cribriform carcinoma (ICC) is a type of malignant tumor with slow growth and good prognosis. The study was a single center retrospective study. The percentage of ICC among patients diagnosed with breast cancer was 0.3% (8/2454 patients). All patients tested positive for estrogen or progesterone receptors and 12.5% (1/8) patients tested positive for human epidermal growth factor receptor type2 (HER2). The present study suggests that the clinicopathological features of ICC are low-grade hormone receptor-positive luminal type with a good prognosis. However, some patients were HER2-positive and require careful follow-up.

浸润性楔形细胞癌(ICC)是一种生长缓慢、预后良好的恶性肿瘤。该研究是一项单中心回顾性研究。在确诊的乳腺癌患者中,ICC的比例为0.3%(8/2454例)。所有患者的雌激素或孕激素受体检测均呈阳性,12.5%(1/8)的患者人表皮生长因子受体2型(HER2)检测呈阳性。本研究表明,ICC的临床病理特征为低级别激素受体阳性管腔型,预后良好。然而,部分患者为 HER2 阳性,需要仔细随访。
{"title":"Characteristics of Invasive Cribriform Carcinoma.","authors":"Ryusei Yoshino, Masaki Nakatsubo, Nanami Ujiie, Akane Ito, Nana Yoshida, Masahiro Kitada","doi":"10.1080/07357907.2024.2383930","DOIUrl":"10.1080/07357907.2024.2383930","url":null,"abstract":"<p><p>Invasive cribriform carcinoma (ICC) is a type of malignant tumor with slow growth and good prognosis. The study was a single center retrospective study. The percentage of ICC among patients diagnosed with breast cancer was 0.3% (8/2454 patients). All patients tested positive for estrogen or progesterone receptors and 12.5% (1/8) patients tested positive for human epidermal growth factor receptor type2 (HER2). The present study suggests that the clinicopathological features of ICC are low-grade hormone receptor-positive luminal type with a good prognosis. However, some patients were HER2-positive and require careful follow-up.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"690-696"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB). 肿瘤突变负荷(TMB)较高的微卫星稳定(MSS)食管癌、胃食管交界癌和胃腺癌的情况和预后。
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1080/07357907.2024.2388107
Ioannis A Voutsadakis

Background: A minority of patients with MSS tumors present a high tumor mutation burden (TMB) without underlying MMR defects.

Methods: Publicly available genomic series were assessed for identification of patients with MSS gastric gastroesophageal junction, and esophageal adenocarcinomas and a high TMB, defined as more than 10 mutations per Mb. These were compared with MSS cancers and a low TMB for genetic alterations and for survival outcomes.

Results: Patients with MSS cancers with high TMB in the MSK series were older but did not differ in other clinicopathologic parameters compared with MSS patients with low TMB. Mutations in tumor suppressors TP53 and APC and oncogenes KRAS and ERBB4 as well as amplifications of ERBB2 were more prevalent in the high TMB group of MSS cancers. Mutations in DDR associated genes, in epigenetic modifiers and in genes associated with immune response were more prevalent in the hIgh TMB group patients. However, high TMB was not associated with an improved survival in MSS gastric/gastroesophageal junction/esophageal adenocarcinomas (Log Rank p = 0.5).

Conclusion: MSS Gastric/gastroesophageal junction/esophageal adenocarcinomas with TMB above 10 mutations per Mb possess a genomic landscape with increased alteration frequencies in common gastroesophageal cancer genes and pathways.

背景:少数MSS肿瘤患者具有高肿瘤突变负荷(TMB),但没有潜在的MMR缺陷:方法:对公开的基因组系列进行评估,以确定MSS胃、胃食管交界处和食管腺癌患者以及高TMB(定义为每Mb超过10个突变)患者。研究人员将这些患者与MSS癌症和低TMB患者的基因改变和生存结果进行了比较:结果:MSK系列中TMB高的MSS癌症患者年龄较大,但与TMB低的MSS患者相比,他们在其他临床病理参数上没有差异。肿瘤抑制基因TP53和APC的突变、致癌基因KRAS和ERBB4的突变以及ERBB2的扩增在高TMB组MSS癌症中更为普遍。在高TMB组患者中,DDR相关基因、表观遗传修饰因子和免疫反应相关基因的突变更为普遍。然而,高TMB与MSS胃/胃食管交界处/食管腺癌生存率的提高无关(对数秩p = 0.5):结论:TMB超过每Mb 10个突变的MSS胃/胃食管交界处/食管腺癌的基因组图谱中,常见的胃食管癌基因和通路的改变频率增加。
{"title":"The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB).","authors":"Ioannis A Voutsadakis","doi":"10.1080/07357907.2024.2388107","DOIUrl":"10.1080/07357907.2024.2388107","url":null,"abstract":"<p><strong>Background: </strong>A minority of patients with MSS tumors present a high tumor mutation burden (TMB) without underlying MMR defects.</p><p><strong>Methods: </strong>Publicly available genomic series were assessed for identification of patients with MSS gastric gastroesophageal junction, and esophageal adenocarcinomas and a high TMB, defined as more than 10 mutations per Mb. These were compared with MSS cancers and a low TMB for genetic alterations and for survival outcomes.</p><p><strong>Results: </strong>Patients with MSS cancers with high TMB in the MSK series were older but did not differ in other clinicopathologic parameters compared with MSS patients with low TMB. Mutations in tumor suppressors <i>TP53</i> and <i>APC</i> and oncogenes <i>KRAS</i> and <i>ERBB4</i> as well as amplifications of <i>ERBB2</i> were more prevalent in the high TMB group of MSS cancers. Mutations in DDR associated genes, in epigenetic modifiers and in genes associated with immune response were more prevalent in the hIgh TMB group patients. However, high TMB was not associated with an improved survival in MSS gastric/gastroesophageal junction/esophageal adenocarcinomas (Log Rank <i>p</i> = 0.5).</p><p><strong>Conclusion: </strong>MSS Gastric/gastroesophageal junction/esophageal adenocarcinomas with TMB above 10 mutations per Mb possess a genomic landscape with increased alteration frequencies in common gastroesophageal cancer genes and pathways.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"697-709"},"PeriodicalIF":1.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Aspirin Use Reduce the Risk for Ovarian Cancer? 服用阿司匹林会降低罹患卵巢癌的风险吗?
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/07357907.2024.2375573
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein

Ovarian cancer is an aggressive malignancy and the leading cause of death among gynecologic cancers. Researchers have evaluated prophylactic medications that potentially avert the manifestation of ovarian cancer, but currently, there are no reliable screening measures for this disease. Nevertheless, the largest study involving aspirin use and ovarian cancer reported a substantive risk reduction from enduring aspirin use. Since there are countervailing data to impugn the potential benefits of aspirin use in staving off ovarian cancer, further research should scrutinize the use of this medication as a prophylactic intervention, especially in women who are at higher risk for developing the disease.

卵巢癌是一种侵袭性恶性肿瘤,也是妇科癌症中的主要死因。研究人员已对可能避免卵巢癌发生的预防性药物进行了评估,但目前还没有针对这种疾病的可靠筛查措施。不过,涉及阿司匹林使用和卵巢癌的最大规模研究报告称,长期服用阿司匹林可大大降低患癌风险。由于有相反的数据对使用阿司匹林预防卵巢癌的潜在益处提出了质疑,因此进一步的研究应该对使用这种药物作为预防性干预措施进行仔细审查,尤其是对那些罹患该疾病风险较高的妇女。
{"title":"Does Aspirin Use Reduce the Risk for Ovarian Cancer?","authors":"John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein","doi":"10.1080/07357907.2024.2375573","DOIUrl":"10.1080/07357907.2024.2375573","url":null,"abstract":"<p><p>Ovarian cancer is an aggressive malignancy and the leading cause of death among gynecologic cancers. Researchers have evaluated prophylactic medications that potentially avert the manifestation of ovarian cancer, but currently, there are no reliable screening measures for this disease. Nevertheless, the largest study involving aspirin use and ovarian cancer reported a substantive risk reduction from enduring aspirin use. Since there are countervailing data to impugn the potential benefits of aspirin use in staving off ovarian cancer, further research should scrutinize the use of this medication as a prophylactic intervention, especially in women who are at higher risk for developing the disease.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"643-646"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Modeling of Long-Term Prognosis After Resection in Typical Pulmonary Carcinoid: A Machine Learning Perspective. 典型肺癌切除术后长期预后的预测模型:机器学习视角
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-15 DOI: 10.1080/07357907.2024.2356002
Min Liang, Jian Huang, Caiyan Liu, Mafeng Chen

Typical Pulmonary Carcinoid (TPC) is defined by its slow growth, frequently necessitating surgical intervention. Despite this, the long-term outcomes following tumor resection are not well understood. This study examined the factors impacting Overall Survival (OS) in patients with TPC, leveraging data from the Surveillance, Epidemiology, and End Results database spanning from 2000 to 2018. We employed Lasso-Cox analysis to identify prognostic features and developed various models using Random Forest, XGBoost, and Cox regression algorithms. Subsequently, we assessed model performance using metrics such as Area Under the Curve (AUC), calibration plot, Brier score, and Decision Curve Analysis (DCA). Among the 2687 patients, we identified five clinical features significantly affecting OS. Notably, the Random Forest model exhibited strong performance, achieving 5- and 7-year AUC values of 0.744/0.757 in the training set and 0.715/0.740 in the validation set, respectively, outperforming other models. Additionally, we developed a web-based platform aimed at facilitating easy access to the model. This study presents a machine learning model and a web-based support system for healthcare professionals, assisting in personalized treatment decisions for patients with TPC post-tumor resection.

典型肺类癌(TPC)的特点是生长缓慢,通常需要手术干预。尽管如此,人们对肿瘤切除术后的长期疗效仍不甚了解。本研究利用监测、流行病学和最终结果数据库中2000年至2018年的数据,研究了影响TPC患者总生存期(OS)的因素。我们采用 Lasso-Cox 分析来确定预后特征,并使用随机森林、XGBoost 和 Cox 回归算法建立了各种模型。随后,我们使用曲线下面积(AUC)、校准图、布赖尔评分和决策曲线分析(DCA)等指标评估了模型的性能。在 2687 例患者中,我们发现了对 OS 有显著影响的五个临床特征。值得注意的是,随机森林模型表现出强劲的性能,在训练集和验证集上,5年和7年的AUC值分别为0.744/0.757和0.715/0.740,优于其他模型。此外,我们还开发了一个基于网络的平台,旨在方便用户访问该模型。本研究为医护人员展示了一个机器学习模型和一个基于网络的支持系统,有助于为肿瘤切除术后的 TPC 患者做出个性化治疗决策。
{"title":"Predictive Modeling of Long-Term Prognosis After Resection in Typical Pulmonary Carcinoid: A Machine Learning Perspective.","authors":"Min Liang, Jian Huang, Caiyan Liu, Mafeng Chen","doi":"10.1080/07357907.2024.2356002","DOIUrl":"10.1080/07357907.2024.2356002","url":null,"abstract":"<p><p>Typical Pulmonary Carcinoid (TPC) is defined by its slow growth, frequently necessitating surgical intervention. Despite this, the long-term outcomes following tumor resection are not well understood. This study examined the factors impacting Overall Survival (OS) in patients with TPC, leveraging data from the Surveillance, Epidemiology, and End Results database spanning from 2000 to 2018. We employed Lasso-Cox analysis to identify prognostic features and developed various models using Random Forest, XGBoost, and Cox regression algorithms. Subsequently, we assessed model performance using metrics such as Area Under the Curve (AUC), calibration plot, Brier score, and Decision Curve Analysis (DCA). Among the 2687 patients, we identified five clinical features significantly affecting OS. Notably, the Random Forest model exhibited strong performance, achieving 5- and 7-year AUC values of 0.744/0.757 in the training set and 0.715/0.740 in the validation set, respectively, outperforming other models. Additionally, we developed a web-based platform aimed at facilitating easy access to the model. This study presents a machine learning model and a web-based support system for healthcare professionals, assisting in personalized treatment decisions for patients with TPC post-tumor resection.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"544-558"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy. 癌症生物学、病理生理学发展及其治疗方法概述:癌症抗血管生成疗法的当前挑战。
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-14 DOI: 10.1080/07357907.2024.2361295
Fares Hezam Al-Ostoot, Salma Salah, Shaukath Ara Khanum

A number of conditions and factors can cause the transformation of normal cells in the body into malignant tissue by changing the normal functions of a wide range of regulatory, apoptotic, and signal transduction pathways. Despite the current deficiency in fully understanding the mechanism of cancer action accurately and clearly, numerous genes and proteins that are causally involved in the initiation, progression, and metastasis of cancer have been identified. But due to the lack of space and the abundance of details on this complex topic, we have emphasized here more recent advances in our understanding of the principles implied tumor cell transformation, development, invasion, angiogenesis, and metastasis. Inhibition of angiogenesis is a significant strategy for the treatment of various solid tumors, that essentially depend on cutting or at least limiting the supply of blood to micro-regions of tumors, leading to pan-hypoxia and pan-necrosis inside solid tumor tissues. Researchers have continued to enhance the efficiency of anti-angiogenic drugs over the past two decades, to identify their potential in the drug interaction, and to discover reasonable interpretations for possible resistance to treatment. In this review, we have discussed an overview of cancer history and recent methods use in cancer therapy, focusing on anti-angiogenic inhibitors targeting angiogenesis formation. Further, this review has explained the molecular mechanism of action of these anti-angiogenic inhibitors in various tumor types and their limitations use. In addition, we described the synergistic mechanisms of immunotherapy and anti-angiogenic therapy and summarizes current clinical trials of these combinations. Many phase III trials found that combining immunotherapy and anti-angiogenic therapy improved survival. Therefore, targeting the source supply of cancer cells to grow and spread with new anti-angiogenic agents in combination with different conventional therapy is a novel method to reduce cancer progression. The aim of this paper is to overview the varying concepts of cancer focusing on mechanisms involved in tumor angiogenesis and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.

许多条件和因素可通过改变各种调节、凋亡和信号转导途径的正常功能,导致体内正常细胞转变为恶性组织。尽管目前还不能完全准确、清晰地了解癌症的作用机制,但已经发现了许多与癌症的发生、发展和转移有因果关系的基因和蛋白质。但由于篇幅所限,且这一复杂课题的细节繁多,我们在此强调我们在理解肿瘤细胞转化、发育、侵袭、血管生成和转移原理方面的最新进展。抑制血管生成是治疗各种实体瘤的重要策略,其本质上取决于切断或至少限制肿瘤微区的血液供应,从而导致实体瘤组织内的泛缺氧和泛坏死。在过去二十年中,研究人员不断提高抗血管生成药物的效率,确定其在药物相互作用中的潜力,并发现对治疗可能产生的耐药性的合理解释。在这篇综述中,我们概述了癌症的历史和最近用于癌症治疗的方法,重点讨论了针对血管生成的抗血管生成抑制剂。此外,本综述还解释了这些抗血管生成抑制剂在各种肿瘤类型中的分子作用机制及其使用限制。此外,我们还介绍了免疫疗法和抗血管生成疗法的协同机制,并总结了目前这些组合疗法的临床试验。许多III期临床试验发现,免疫疗法和抗血管生成疗法联合使用可提高生存率。因此,针对癌细胞生长和扩散的源头,将新型抗血管生成药物与不同的常规疗法相结合,是减少癌症进展的一种新方法。本文旨在概述癌症的各种概念,重点关注肿瘤血管生成的相关机制,并概述癌症治疗中抗血管生成策略的最新趋势。
{"title":"An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy.","authors":"Fares Hezam Al-Ostoot, Salma Salah, Shaukath Ara Khanum","doi":"10.1080/07357907.2024.2361295","DOIUrl":"10.1080/07357907.2024.2361295","url":null,"abstract":"<p><p>A number of conditions and factors can cause the transformation of normal cells in the body into malignant tissue by changing the normal functions of a wide range of regulatory, apoptotic, and signal transduction pathways. Despite the current deficiency in fully understanding the mechanism of cancer action accurately and clearly, numerous genes and proteins that are causally involved in the initiation, progression, and metastasis of cancer have been identified. But due to the lack of space and the abundance of details on this complex topic, we have emphasized here more recent advances in our understanding of the principles implied tumor cell transformation, development, invasion, angiogenesis, and metastasis. Inhibition of angiogenesis is a significant strategy for the treatment of various solid tumors, that essentially depend on cutting or at least limiting the supply of blood to micro-regions of tumors, leading to pan-hypoxia and pan-necrosis inside solid tumor tissues. Researchers have continued to enhance the efficiency of anti-angiogenic drugs over the past two decades, to identify their potential in the drug interaction, and to discover reasonable interpretations for possible resistance to treatment. In this review, we have discussed an overview of cancer history and recent methods use in cancer therapy, focusing on anti-angiogenic inhibitors targeting angiogenesis formation. Further, this review has explained the molecular mechanism of action of these anti-angiogenic inhibitors in various tumor types and their limitations use. In addition, we described the synergistic mechanisms of immunotherapy and anti-angiogenic therapy and summarizes current clinical trials of these combinations. Many phase III trials found that combining immunotherapy and anti-angiogenic therapy improved survival. Therefore, targeting the source supply of cancer cells to grow and spread with new anti-angiogenic agents in combination with different conventional therapy is a novel method to reduce cancer progression. The aim of this paper is to overview the varying concepts of cancer focusing on mechanisms involved in tumor angiogenesis and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"559-604"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. 人工智能与癌症临床研究:癌症化疗患者发热性中性粒细胞减少症的 III 风险预测模型。
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-04 DOI: 10.1080/07357907.2024.2370692
Gary H Lyman, Nicole M Kuderer
{"title":"Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy.","authors":"Gary H Lyman, Nicole M Kuderer","doi":"10.1080/07357907.2024.2370692","DOIUrl":"10.1080/07357907.2024.2370692","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"539-543"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barthel Index and Age as Predictors of Discharge Destination in Patients with Glioblastoma. 作为胶质母细胞瘤患者出院去向预测因素的巴特尔指数和年龄
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1080/07357907.2024.2371367
Hirotomo Shibahashi, Miyuki Murakawa, Kenichiro Matsuda, Yuya Takakubo, Michiaki Takagi

This study aimed to investigate the predictive factors of transfer of glioblastoma multiforme (GBM) patients who underwent rehabilitation in acute care hospitals. We retrospectively identified 85 patients with GBM who underwent rehabilitation at our hospital. Multivariable logistic regression analysis showed that age and Barthel index (BI) at rehabilitation initiation significantly influenced the discharge destination. Cut-off values for these factors were 76 years of age and 30 BI points. These findings could help predict the discharge destination and the choice of rehabilitation strategies of newly diagnosed patients with GBM admitted to an acute care hospital.

本研究旨在调查在急诊医院接受康复治疗的多形性胶质母细胞瘤(GBM)患者转院的预测因素。我们回顾性地确定了85名在本院接受康复治疗的多形性胶质母细胞瘤患者。多变量逻辑回归分析表明,开始康复时的年龄和巴特尔指数(BI)对出院去向有显著影响。这些因素的临界值为 76 岁和 30 个 BI 点。这些发现有助于预测入住急症医院的新确诊 GBM 患者的出院去向和康复策略的选择。
{"title":"Barthel Index and Age as Predictors of Discharge Destination in Patients with Glioblastoma.","authors":"Hirotomo Shibahashi, Miyuki Murakawa, Kenichiro Matsuda, Yuya Takakubo, Michiaki Takagi","doi":"10.1080/07357907.2024.2371367","DOIUrl":"10.1080/07357907.2024.2371367","url":null,"abstract":"<p><p>This study aimed to investigate the predictive factors of transfer of glioblastoma multiforme (GBM) patients who underwent rehabilitation in acute care hospitals. We retrospectively identified 85 patients with GBM who underwent rehabilitation at our hospital. Multivariable logistic regression analysis showed that age and Barthel index (BI) at rehabilitation initiation significantly influenced the discharge destination. Cut-off values for these factors were 76 years of age and 30 BI points. These findings could help predict the discharge destination and the choice of rehabilitation strategies of newly diagnosed patients with GBM admitted to an acute care hospital.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"619-626"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1